Admetsys, a company headquartered in Boston, has developed a system for controlling blood glucose levels in critical care patients. Essentially an artificial pancreas, the system relies on a lab-on-a-chip that’s embedded within an intravenous catheter to measure glucose and lactic acid, automatically supplying insulin or glucose to keep the patient within normal range.
Measurements are done about every five minutes, and since sensing is embedded there’s no blood drawn out of the patient, no fingers are pricked. Moreover, once the catheter is placed and the system is initiated, there’s nothing for a nurse to do in terms of blood sugar regulation.
The system is moving through the regulatory frameworks in the U.S. and Europe, but the company has yet to receive any approvals.
Here’s Timothy Valk, the co-founder and Chief Scientist of Admetsys, discussing the company and its technology on CNBC:
Admetsys on its artificial pancreas for treating diabetes from CNBC…
You may be interested
Three takeaways on the VA, VistA and government health ITFrank - Apr 24, 2019
A new study from the U.S. Government Accountability Office dug deeper into what’s happening with the Department of Veterans Affairs and…
People are talking about this Bojack Horseman episode in light of the Las Vegas mass shootingFrank - Apr 24, 2019
Frank's source: http://www.independent.co.uk/arts-entertainment/tv/news/bojack-horseman-season-4-thoughts-and-prayers-a7982226.html
Netflix sets release date for ‘terrifying’ supernatural series DarkFrank - Apr 24, 2019
Frank's source: http://www.independent.co.uk/arts-entertainment/tv/news/dark-netflix-release-date-german-language-teaser-trailer-a7982216.html